Andrew Rappaport - 21 Nov 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
21 Nov 2025
Net transactions value
+$13,989
Form type
4
Filing time
25 Nov 2025, 18:00:11 UTC
Previous filing
13 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RAPPAPORT ANDREW Director C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO /s/ Shane Kovacs, Attorney-in-Fact 25 Nov 2025 0001162157

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Options Exercise $13,989 +35,868 $0.3900 35,868 21 Nov 2025 Direct
transaction OLMA Common Stock Gift $0 -35,868 -100% $0.000000 0 25 Nov 2025 Direct F1
holding OLMA Common Stock 385,965 21 Nov 2025 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (right to buy) Options Exercise $0 -35,868 -100% $0.000000 0 21 Nov 2025 Common Stock 35,868 $0.3900 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation.
F2 The shares are held by the Rappaport Family Trust, of which the reporting person is co-trustee.
F3 The shares subject to the option are fully vested.